News
News Center
Ensuring Public Medication Safety: Jiuzhitang Makes a Solemn Commitment
来源：Jiuzhitang Group
2019-12-24
On November 28, the "2nd Forum on Corporate Responsibility for Safe Medication Use and Dialogue on Traditional Chinese Medicine Quality & Development," guided by the National Medical Products Administration and hosted by China Economic Net, with joint sponsorship from the China Association of Traditional Chinese Medicine and the All-China Federation of Industry and Commerce Pharmaceutical Chamber of Commerce, was held in Beijing.
The forum focuses on the theme of "Innovation and Medication Safety," delving into how to further stimulate corporate innovation amid the continuously improving national innovation policies and environment, as well as addressing the safety challenges posed by innovative drugs. Meanwhile, experts and industry leaders engage in a dialogue centered on the quality and development of traditional Chinese medicine—topics of significant interest to the sector.
At the meeting, Meng Xiangyun, Chief Engineer of Jiuzhitang Group, delivered a keynote speech on "Leading High-Quality Development of the Traditional Chinese Medicine Industry Through Innovation." During his speech, he highlighted that China's pharmaceutical market has transitioned from an era of rapid growth to one focused on high-quality development. Under these new circumstances and evolving demands, TCM enterprises must proactively shift their development strategies, making innovation the primary driving force behind corporate growth. By continuously enhancing their innovative capabilities, companies should place great emphasis on the clinical efficacy, quality, and scientific value of their products—ultimately creating cutting-edge solutions that are not only premium in quality and safety but also deliver significant clinical benefits. This approach will ensure superior product performance and earn lasting trust and recognition in the market, collectively propelling the high-quality advancement of both the TCM industry and its broader mission.
Meanwhile, Meng Xiangyun also shared with the attending delegates Jiu Zhitang's explorations and achievements in areas such as intelligent manufacturing of traditional Chinese medicine, evidence-based medicine and re-evaluation of its marketed products, and regenerative medicine. Moving forward, Jiu Zhitang will remain guided by public health needs, continuously focusing on quality benchmarks and traceability of authentic medicinal materials used in its existing products. The company will actively engage in research evaluating the clinical value of traditional Chinese medicines and classic prescriptions, further enhancing product quality. At the same time, Jiu Zhitang will relentlessly innovate and develop new products, striving to deliver even better healthcare solutions to the public.
On the forum, Jiuzhitang Group also joined representatives from 30 leading pharmaceutical companies—including Yangtze River Pharmaceutical Group, Yabao Pharmaceutical, and Guangzhou Pharmaceutical Group—from diverse sectors such as biopharmaceuticals, chemical drugs, traditional Chinese medicine, medical devices, and vaccines—to jointly launch the "2020 Innovation and Safe Medication Declaration." This marked a solemn commitment to fostering innovation, ensuring public access to safe medicines, and driving the industry toward sustainable, healthy growth.
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy